239 related articles for article (PubMed ID: 34417810)
21. Dopamine agonists in restless leg syndrome treatment and their effects on sleep parameters: A systematic review and meta-analysis.
Yeh WC; Li YS; Chang YP; Hsu CY
Sleep Med; 2024 Jul; 119():379-388. PubMed ID: 38761607
[TBL] [Abstract][Full Text] [Related]
22. Comparison of pregabalin with pramipexole for restless legs syndrome.
Allen RP; Chen C; Garcia-Borreguero D; Polo O; DuBrava S; Miceli J; Knapp L; Winkelman JW
N Engl J Med; 2014 Feb; 370(7):621-31. PubMed ID: 24521108
[TBL] [Abstract][Full Text] [Related]
23. Pramipexole: in restless legs syndrome.
McCormack PL; Siddiqui MA
CNS Drugs; 2007; 21(5):429-37; discussion 438-40. PubMed ID: 17447832
[TBL] [Abstract][Full Text] [Related]
24. Critical review of ropinirole and pramipexole - putative dopamine D(3)-receptor selective agonists - for the treatment of RLS.
Varga LI; Ako-Agugua N; Colasante J; Hertweck L; Houser T; Smith J; Watty AA; Nagar S; Raffa RB
J Clin Pharm Ther; 2009 Oct; 34(5):493-505. PubMed ID: 19744006
[TBL] [Abstract][Full Text] [Related]
25. Restless legs syndrome: pathophysiology and modern management.
Nagandla K; De S
Postgrad Med J; 2013 Jul; 89(1053):402-10. PubMed ID: 23524988
[TBL] [Abstract][Full Text] [Related]
26. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome.
Bogan RK
Clin Ther; 2014 Mar; 36(3):436-55. PubMed ID: 24636821
[TBL] [Abstract][Full Text] [Related]
27. Increased Risk for New-Onset Psychiatric Adverse Events in Patients With Newly Diagnosed Primary Restless Legs Syndrome Who Initiate Treatment With Dopamine Agonists: A Large-Scale Retrospective Claims Matched-Cohort Analysis.
Hankin C; Lee D; Garcia-Borreguero D; Wang Z
J Clin Sleep Med; 2019 Sep; 15(9):1225-1232. PubMed ID: 31538593
[TBL] [Abstract][Full Text] [Related]
28. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group.
Garcia-Borreguero D; Kohnen R; Silber MH; Winkelman JW; Earley CJ; Högl B; Manconi M; Montplaisir J; Inoue Y; Allen RP
Sleep Med; 2013 Jul; 14(7):675-84. PubMed ID: 23859128
[TBL] [Abstract][Full Text] [Related]
29. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease.
Maestri M; Fulda S; Ferini-Strambi L; Zucconi M; Marelli S; Staedler C; Bassetti CL; Manconi M
Sleep Med; 2014 May; 15(5):570-5. PubMed ID: 24767724
[TBL] [Abstract][Full Text] [Related]
30. Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Winkelman JW; Armstrong MJ; Allen RP; Chaudhuri KR; Ondo W; Trenkwalder C; Zee PC; Gronseth GS; Gloss D; Zesiewicz T
Neurology; 2016 Dec; 87(24):2585-2593. PubMed ID: 27856776
[TBL] [Abstract][Full Text] [Related]
31. Proposed dose equivalence between clonazepam and pramipexole in patients with restless legs syndrome.
Shinno H; Oka Y; Otsuki M; Tsuchiya S; Mizuno S; Kawada S; Innami T; Sasaki A; Hineno T; Sakamoto T; Inami Y; Nakamura Y; Horiguchi J
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):522-6. PubMed ID: 20156514
[TBL] [Abstract][Full Text] [Related]
32. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists.
Meyers J; Candrilli S; Allen R; Manjunath R; Calloway M
Manag Care; 2012 Oct; 21(10):44-51. PubMed ID: 23156076
[TBL] [Abstract][Full Text] [Related]
33. Long-term use of pramipexole in the management of restless legs syndrome.
Lipford MC; Silber MH
Sleep Med; 2012 Dec; 13(10):1280-5. PubMed ID: 23036265
[TBL] [Abstract][Full Text] [Related]
34. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
35. Pramipexole in the treatment of restless legs syndrome: a follow-up study.
Montplaisir J; Denesle R; Petit D
Eur J Neurol; 2000 May; 7 Suppl 1():27-31. PubMed ID: 11054156
[TBL] [Abstract][Full Text] [Related]
36. Restless legs syndrome augmentation among Japanese patients receiving pramipexole therapy: Rate and risk factors in a retrospective study.
Takahashi M; Nishida S; Nakamura M; Kobayashi M; Matsui K; Ito E; Usui A; Inoue Y
PLoS One; 2017; 12(3):e0173535. PubMed ID: 28264052
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.
Quilici S; Abrams KR; Nicolas A; Martin M; Petit C; Lleu PL; Finnern HW
Sleep Med; 2008 Oct; 9(7):715-26. PubMed ID: 18226947
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety and dose-response of pramipexole in Japanese patients with primary restless legs syndrome: randomized trial.
Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
Neuropsychobiology; 2011; 63(1):35-42. PubMed ID: 21063131
[TBL] [Abstract][Full Text] [Related]
39. Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis.
Zintzaras E; Kitsios GD; Papathanasiou AA; Konitsiotis S; Miligkos M; Rodopoulou P; Hadjigeorgiou GM
Clin Ther; 2010 Feb; 32(2):221-37. PubMed ID: 20206780
[TBL] [Abstract][Full Text] [Related]
40. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
